DaVita HealthCare Partners Inc. Announces Results as of Consent Payment Deadline and Execution of Supplemental Indenture relate

   DaVita HealthCare Partners Inc. Announces Results as of Consent Payment
Deadline and Execution of Supplemental Indenture related to its 6 3/8% Senior
                                Notes due 2018

PR Newswire

DENVER, June 18, 2014

DENVER, June 18, 2014 /PRNewswire/ --DaVita HealthCare Partners Inc. (NYSE:
DVA) (the "Company") today announced the execution of the supplemental
indenture related to its previously announced consent solicitation (the
"Consent Solicitation") for amendments to the Company's 6 3/8% Senior Notes
due 2018 (the "Notes") and the indenture pursuant to which the Notes were
issued (the "Indenture"). The supplemental indenture was executed after
receipt of consents from the holders of a majority in principal amount of


The amendments will eliminate substantially all of the restrictive covenants
and certain events of default from the Notes and the Indenture.

The Consent Solicitation commenced concurrently with the Company's tender
offer to purchase for cash (the "Tender Offer" and, together with the Consent
Solicitation, the "Offer") any and all of the Notes. As of 5:00 p.m., New
York City time, on June 17, 2014 (the "Consent Payment Deadline"),
approximately $483 million of the $775 million aggregate outstanding principal
amount of Notes have been tendered pursuant to the Tender Offer. The Offer is
being made pursuant to an Offer to Purchase and Consent Solicitation Statement
(the "Statement") and the related Letter of Transmittal and Consent, each
dated June 4, 2014. Subject to the terms and conditions of the Offer,
including the Financing Condition (as defined in the Statement), the Company
expects to make payment on June 24, 2014 (the "Initial Payment Date") to the
holders of Notes that have validly tendered their Notes one business day prior
to the Initial Payment Date. The supplemental indenture will become operative
following the Initial Payment Date. Holders may no longer withdraw their
Notes and thereby revoke their consents. Holders who tendered their Notes
before the Consent Payment Deadline are eligible to receive the Total
Consideration (as defined in the Statement). Holders must tender their Notes
before midnight, New York City time, at the end of July 1, 2014 in order to
receive the Tender Offer Consideration (as defined in the Statement).

The Tender Offer will expire at midnight, New York City time, at the end of
July 1, 2014 unless extended or earlier terminated.

DaVita HealthCare Partners Inc. has engaged Wells Fargo Securities, LLC and
Barclays Capital Inc. as the Dealer Managers and Solicitation Agents for the
Offer. Questions regarding the Offer may be directed to Wells Fargo
Securities, LLC at (866) 309-6316 (toll free) and (704) 410-4760 (collect) and
Barclays Capital Inc. at (800) 438-3242 (toll free) and (212) 528-7581
(collect). Copies of the Statement and Letter of Transmittal and Consent may
be obtained from the Information Agent for the Offer, D. F. King & Co., Inc.,
at (212) 269-5550 (banks and brokers) or (800) 967-4607 (toll free) or by
email at davita@dfking.com.

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy any debt securities. This release contains forward-looking
statements within the meaning of the federal securities laws, including
statements related to anticipated refinancing transactions. Factors that
could impact future results include the uncertainties associated with the risk
factors set forth in our SEC filings, including our annual report on Form 10-K
for the year ended December 31, 2013, our subsequent quarterly and annual
reports and our current reports on Form 8-K. The forward-looking statements
should be considered in light of these risks and uncertainties.

These risks and uncertainties include, but are not limited to, and are
qualified in their entirety by reference to the full text of those risk
factors in our SEC filings relating to:

  othe concentration of profits generated by higher-paying commercial payor
    plans for which there is continued downward pressure on average realized
    payment rates, and a reduction in the number of patients under such plans,
    which may result in the loss of revenues or patients,
  oa reduction in government payment rates under the Medicare End Stage Renal
    Disease program or other government-based programs,
  othe impact of health care reform legislation that was enacted in the
    United States in March 2010,
  othe impact of the Center for Medicare and Medicaid Services (CMS) 2014
    Medicare Advantage benchmark structure,
  othe impact of the American Taxpayer Relief Act,
  othe impact of disruptions in federal government operations and funding,
  ochanges in pharmaceutical or anemia management practice patterns, payment
    policies, or pharmaceutical pricing,
  olegal compliance risks, including our continued compliance with complex
    government regulations and current or potential investigations by various
    government entities and related government or private-party proceedings,
    including risks relating to the resolution of the 2010 and 2011 U.S.
    Attorney Physician Relationship Investigations, such as restrictions on
    our business and operations required by a corporate integrity agreement
    and other settlement terms, and the financial impact thereof,
  oour ability to maintain contracts with physician medical directors,
    changing affiliation models for physicians, and the emergence of new
    models of care introduced by the government or private sector, that may
    erode our patient base and reimbursement rates,
  oour ability to complete acquisitions, mergers or dispositions that we
    might be considering or announce, or to integrate and successfully operate
    any business we may acquire or have acquired, including HealthCare
    Partners (HCP), or to expand our operations and services to markets
    outside the United States,
  othe risk that we might invest material amounts of capital and incur
    significant costs in connection with the growth and development of our
    international operations, yet we might not be able to operate them
    profitably anytime soon, if at all, 
  orisks arising from the use of accounting estimates, judgments and
    interpretations in our financial statements,
  othe risk that the cost of providing services under HCP's agreements may
    exceed our compensation,
  othe risk that reductions in reimbursement rates, including Medicare
    Advantage rates, and future regulations may negatively impact HCP's
    business, revenue and profitability,
  othe risk that HCP may not be able to successfully establish a presence in
    new geographic regions or successfully address competitive threats that
    could reduce its profitability,
  othe risk that a disruption in HCP's healthcare provider networks could
    have an adverse effect on HCP's business operations and profitability,
  othe risk that reductions in the quality ratings of health maintenance
    organization plan customers of HCP could have an adverse effect on HCP's
    business, or
  othe risk that health plans that acquire health maintenance organizations
    may not be willing to contract with HCP or may be willing to contract only
    on less favorable terms.

We base our forward-looking statements on information currently available to
us at the time of this release, and we undertake no obligation to update or
revise any forward-looking statements, whether as a result of changes in
underlying factors, new information, future events or otherwise.

Contact: Jim Gustafson
Investor Relations
DaVita HealthCare Partners Inc.
(310) 536-2585

Logo - http://photos.prnewswire.com/prnh/20140318/DC85712LOGO

SOURCE DaVita HealthCare Partners Inc.

Website: http://www.davita.com
Press spacebar to pause and continue. Press esc to stop.